Search Results - "Gordon, Kenneth B."

Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.

Authors: Gordon, Kenneth B. Tada, Yayoi Anadkat, Milan J. et al.

Source: Dermatology & Therapy. Jun2025, Vol. 15 Issue 6, p1587-1594. 8p.

Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.

Authors: Gordon, Kenneth B. Tada, Yayoi Anadkat, Milan J. et al.

Source: Dermatology & Therapy. Feb2025, Vol. 15 Issue 2, p395-411. 17p.

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials.

Authors: Gordon, Kenneth B. Blauvelt, Andrew Bachelez, Hervé et al.

Source: Dermatology & Therapy. Sep2024, Vol. 14 Issue 9, p2523-2538. 16p.

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.

Authors: Blauvelt, Andrew Gordon, Kenneth B. Lee, Patricia et al.

Source: Journal of Dermatological Treatment. Jun2022, Vol. 33 Issue 4, p2085-2093. 9p.

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.

Authors: Gordon, Kenneth B Langley, Richard G Warren, Richard B et al.

Source: British Journal of Dermatology. Apr2024, Vol. 190 Issue 4, p477-485. 9p.

Biologic Sequence for the Treatment of Psoriatic Arthritis Following Nonresponse: A Narrative Review.

Authors: Boswell, Nicole D. Ries, Alexa Gordon, Kenneth B. et al.

Source: Dermatology & Therapy. Sep2025, Vol. 15 Issue 9, p2335-2360. 26p.

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.

Authors: Morita, Akimichi Strober, Bruce Burden, A David et al.

Source: Lancet. 10/28/2023, Vol. 402 Issue 10412, p1541-1551. 11p.

Subjects: Boehringer Ingelheim Pharmaceuticals Inc., Psoriasis, Receptor antibodies, Monoclonal antibodies, Sex distribution, Medical screening

Clinical Action Points.

Authors: Ruderman, Eric M. Gordon, Kenneth B.

Source: Healio Rheumatology. Sep2025, Vol. 10 Issue 9, p38-38. 1/3p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Eruptive Xanthoma During Antiretroviral Therapy.

Authors: Vaughn, Olushola L. Akinshemoyin Gordon, Kenneth B. Wainaina, J. Njeri

Source: Journal of Microbiology & Infectious Diseases. 2019, Vol. 9 Issue 1, p43-45. 3p.

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.

Authors: Gordon, Kenneth B. Gottlieb, Alice B. Leonardi, Craig L. et al.

Source: Journal of Dermatological Treatment. Feb2006, Vol. 17 Issue 1, p9-17. 9p. 1 Diagram, 5 Charts, 2 Graphs.

Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.

Authors: Patel, Toral Gordon, Kenneth B.

Source: Dermatologic Therapy. Oct2004, Vol. 17 Issue 5, p427-431. 5p.

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

Authors: Gordon, Kenneth B Foley, Peter Krueger, James G et al.

Source: Lancet. 2/6/2021, Vol. 397 Issue 10273, p475-486. 12p.

Subjects: Drug efficacy, UCB SA, Psoriasis, Monoclonal antibodies, Patient safety, Immunoglobulin A, Gingivitis, Therapeutic use of monoclonal antibodies, Research, Research methodology, Medical cooperation, Evaluation research, Drug administration, Comparative studies, Quality of life, Blind experiment

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.

Authors: Reich, Kristian Papp, Kim A Blauvelt, Andrew et al.

Source: Lancet. 2/6/2021, Vol. 397 Issue 10273, p487-498. 12p.

Subjects: Drug efficacy, UCB SA, Body surface area, Placebos, Psoriasis, Comparator circuits, Gingivitis, Therapeutic use of monoclonal antibodies, Research, Research methodology, Medical cooperation, Evaluation research, Comparative studies, Blind experiment, Dermatologic agents

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.

Authors: Blauvelt, Andrew Langley, Richard G. Gordon, Kenneth B. et al.

Source: Dermatology & Therapy. Dec2023, Vol. 13 Issue 12, p3031-3042. 12p.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.

Authors: Gordon, Kenneth B. Puig, Lluís Foley, Peter et al.

Source: Lancet. 8/25/2018, Vol. 392 Issue 10148, p650-661. 12p. 4 Charts, 4 Graphs.

Subjects: Psoriasis treatment, Monoclonal antibodies, Interleukin-23, Cytokines, Placebos, Therapeutic use of immunoglobulins, Subcutaneous injections, Comparative studies, Dermatologic agents, Interleukins, Research methodology, Medical cooperation, Psoriasis, Research, Statistical sampling, Tumor necrosis factors, Evaluation research, Randomized controlled trials, Treatment effectiveness, Blind experiment, Severity of illness index, Pharmacodynamics

Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.

Authors: Warren, Richard B. Hunter, Hamish J. A. Papp, Kim A. et al.

Source: PLoS ONE. 1/23/2026, Vol. 21 Issue 1, p1-19. 19p.

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.

Authors: Crowley, Jeffrey J. Langley, Richard G. Gordon, Kenneth B. et al.

Source: Dermatology & Therapy. Feb2022, Vol. 12 Issue 2, p561-575. 15p.

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Authors: Thaçi, Diamant Strober, Bruce Gordon, Kenneth B. et al.

Source: Dermatology & Therapy. Feb2022, Vol. 12 Issue 2, p495-510. 16p.